Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,933 | 105,895 | 44,871 | 41,256 | -13,579 |
| Depreciation Amortization | -221 | -1,204 | -293 | 73 | 86 |
| Income taxes - deferred | -2,999 | -11,519 | -11,549 | -12,543 | -1,852 |
| Accounts payable and accrued liabilities | -1,468 | 326 | -29 | -567 | 166 |
| Other Working Capital | 75,830 | 120,471 | 192,853 | 209,733 | 51,937 |
| Other Operating Activity | 7,070 | 24,572 | 18,752 | 13,161 | 6,281 |
| Operating Cash Flow | $73,279 | $238,541 | $244,605 | $251,113 | $43,039 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -42 | -34 | -34 | N/A |
| Purchase Of Investment | -43,407 | -248,217 | -183,288 | -58,542 | -1,968 |
| Sale Of Investment | 96,000 | 142,975 | 77,450 | 52,950 | 32,600 |
| Investing Cash Flow | $52,593 | $-105,284 | $-105,872 | $-5,626 | $30,632 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 241 | 786 | 298 | 20 | 20 |
| Common Stock Repurchased | -5,818 | -4,034 | -2,055 | -1,377 | -874 |
| Financing Cash Flow | $-5,577 | $-3,248 | $-1,757 | $-1,357 | $-854 |
| Beginning Cash Position | 168,642 | 38,633 | 38,633 | 38,633 | 38,633 |
| End Cash Position | 288,937 | 168,642 | 175,609 | 282,763 | 111,450 |
| Net Cash Flow | $120,295 | $130,009 | $136,976 | $244,130 | $72,817 |
| Free Cash Flow | |||||
| Operating Cash Flow | 73,279 | 238,541 | 244,605 | 251,113 | 43,039 |
| Capital Expenditure | N/A | -42 | -34 | -34 | N/A |
| Free Cash Flow | 73,279 | 238,499 | 244,571 | 251,079 | 43,039 |